A new study led by researchers at The University of Texas MD Anderson Cancer Center has discovered that co-occurring mutations in three tumor suppressor genes—KEAP1, SMARCA4 and CDKN2A—are linked with poor clinical outcomes in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitors adagrasib or sotorasib.
Mutations in three key genes associated with poor outcomes in lung cancer patients treated with KRAS G12C inhibitors
A new study led by researchers at The University of Texas MD Anderson Cancer Center has discovered that co-occurring mutations in three tumor suppressor genes—KEAP1, SMARCA4 and CDKN2A—are linked with poor clinical outcomes in patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) treated with the KRAS G12C inhibitors adagrasib or sotorasib.